Indications
Urothelial bladder carcinoma Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):
After prior chemotherapy, or
Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or
Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression. ... Read moreAtezolizumab is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC):
After prior chemotherapy, or
Who are considered cisplatin ineligibleand whose tumours have a PD-L1 expression ≥ 5%, or
Who are not eligible for any platinum-containing chemotherapy regardless of level of tumor PD-L1 expression.
Atezolizumab is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer NSCLC after prior chemotherapy.
Dosage And Administration
General: Atezolizumab must be administered as an intravenousinfusion under the supervision of a qualified healthcare professional. Do not administer as an IV push or bolus. Substitution by any other biological medicinal product requires the consent of the prescribing physician. The initial dose of Atezolizumab must be administered over 60 minutes. If the first infusion is tolerated all subsequent infusions may be administered over 30 minutes. The recommended dose of Atezolizumab is either:
1200 mg administered by IV infusion every 3 weeks or
1680 mg administered by IV infusion every 4 weeks.
1L cisplatin-ineligible mUC: Patients should be selected for treatment based on the tumor expression of PD-L1 confirmed by a validated test
Side Effects
This Information Is Not Available. Ask Your Doctor Or Pharmacist.
Precautions And Warnings
Immune-related pneumonitis: Cases of pneumonitis, including fatal cases, have been observed in clinical trials with Atezolizumab. Patients should be monitored for signs and symptoms of pneumonitis. Immune-related hepatitis: Cases of hepatitis, some leading to fatal outcomes, have been observed in clinical trials with Atezolizumab. Patients should be monitored for signs and symptoms of hepatitis. Monitor aspartate aminotransferase (AST), alanine aminotransferase (ALT) and bilirubin prior to and periodically during treatment with Atezolizumab. Consider appropriate management of patients with abnormal liver function tests (LFTs) at baseline.Immune-related colitis: Cases of diarrhea or colitis have been observed in clinical trials with Atezolizumab. Patients should be monitored for signs and symptoms of colitis. Immune-related endocrinopathies: Hypothyroidism, hyperthyroidism, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have been observed in clinical trials with Atezolizumab. Patients should be monitored for clinical signs and symptoms of endocrinopathies. Monitor thyroid function prior to and periodically during treatment with Atezolizumab. Consider appropriate management of patients with abnormal thyroid function tests at baseline. Patients with abnormal thyroid function tests who are asymptomatic may receive Atezolizumab.
Pregnancy And Lactation
There are no clinical studies of Atezolizumab in pregnant women. Atezolizumab is not recommended during pregnancy unless the potential benefit for the mother outweighs the potential risk to the fetusIt is not known whether Atezolizumab is excreted in human breast milk. No studies have been conducted to assess the impact of Atezolizumab on milk production or its presence in breast milk.Asthe potential for harm to the nursing infant is unknown,a decision must be madeto either discontinue breast-feeding ordiscontinue Atezolizumabtherapy.